Actively Recruiting
Association Between Elevated Plasma D-dimer in Adult Community-acquired Pneumonia Patients and Severity of Inflammatory Response and Survival
Led by Ain Shams University · Updated on 2026-02-24
50
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to explore how high levels of plasma D-dimer relate to the inflammatory response and survival outcomes in adults diagnosed with community-acquired pneumonia (CAP). CAP is a common infection that can be serious and affects many people worldwide. The study focuses on understanding the link between D-dimer levels, inflammation severity, and patient survival. Participants in this observational study will include adults aged 18 and older diagnosed with CAP based on symptoms, lab tests, and chest X-rays, excluding those with signs of COVID-19 pneumonia. Each participant will have blood samples taken to measure D-dimer levels, along with assessments including a full medical history, clinical examination, laboratory tests like white blood cell count and C-reactive protein, and radiological findings. Severity of illness will also be evaluated using the CURB-65 score. Throughout the study, researchers will monitor the correlation between D-dimer levels and the severity of pneumonia over six months. Participants will undergo standard clinical assessments and laboratory tests without receiving experimental treatments. The study will collect and analyze data to better understand how inflammation and D-dimer levels affect outcomes in CAP patients, with no additional interventions beyond routine care.
CONDITIONS
Brief Title
Association Between Plasma D Dimer in Adult CAP and Severity of Inflammatory Response and Survival
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to the Chest department or visiting the outpatient clinic at Ain-Shams University Hospitals with community-acquired pneumonia
- Age 18 years or older
- Diagnosis of community-acquired pneumonia based on clinical symptoms, laboratory findings, and radiological evidence
You will not qualify if you...
- History of coagulation disorders, cancer, or other chronic diseases
- Presence of clinical or radiological signs suggesting COVID-19 pneumonia
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At enrollment
Participants undergo clinical examination, laboratory tests including blood samples for D-dimer, and radiological assessment to evaluate community-acquired pneumonia severity.
1 visit (in-person)
Duration - 6 months
Participants are observed for up to 6 months to assess the correlation between plasma D-dimer levels and severity of pneumonia outcomes.
Trial Site Locations
Total: 1 location
1
Ain Shams University hospitals
Cairo, Egypt
Actively Recruiting
Research Team
H
Hieba Gamal Ezzelregal
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here